Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05304234 · ClinicalTrials.gov registry record · Phase 2
Liver Cancer Disparities in American Indian and Alaska Native Persons
A Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver, sponsored by University of Washington.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05304234: Recruiting Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver, sponsored by University of Washington.
NCT05304234 is a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver that is actively recruiting participants, run by University of Washington. The registered enrollment target is 200 participants, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (22% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05304234, a Phase 2 study of Hepatocellular Carcinoma and Cirrhosis, Liver, is actively recruiting participants, sponsored by University of Washington.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Ultrasound or abbreviated MRI
Study Locations (1)
Oklahoma
- Cherokee Nation Health Service - Tahlequah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What NCT05304234 shows while recruiting
NCT05304234 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 256-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (22% lower).
The record links to 3 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound or abbreviated MRI is the first listed.
NCT05304234 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT05304234 about?
NCT05304234 is a clinical study titled "Liver Cancer Disparities in American Indian and Alaska Native Persons". We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
What is the current status of trial NCT05304234?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2022-04-01. Estimated completion is 2026-09-01.
What conditions does trial NCT05304234 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Liver, Hepatitis B.
What interventions are being tested in trial NCT05304234?
The interventions under investigation include: Ultrasound or abbreviated MRI (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05304234?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05304234 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05304234's enrollment target sits among peer trials
200 42nd of 145 higher than 104 of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI